RedHill Biopharma is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill's pipeline includes several drug candidates in advanced clinical development stages, including three Phase III-stage programs. The company promotes GI products in the U.S.

424B5 | Prospectus

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Redhill Biopharma Ltd (RDHL US)

424B5 | Prospectus

424B3 | Prospectus

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 (PDF)

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 (PDF)

US SEC Form 424B5 for Redhill Biopharma Ltd

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)